Max Gelman
@maxgelman.bsky.social
Reporting on pharma and biotech for Endpoints News. Baseball fan, Northwestern alum. Message me on Signal: maxgelman.37
More #ASCO25 news this morning!
Feasibility questions about AstraZeneca's breast cancer drug: endpts.com/asco25-astra...
Researchers debate how to best use checkpoint inhibitors: endpts.com/asco25-resea...
Takeda and Protagonist's plenary data: endpts.com/asco25-taked...
Feasibility questions about AstraZeneca's breast cancer drug: endpts.com/asco25-astra...
Researchers debate how to best use checkpoint inhibitors: endpts.com/asco25-resea...
Takeda and Protagonist's plenary data: endpts.com/asco25-taked...
AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain
AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects to exceed more than $5 billion in annual peak sales.
endpts.com
June 1, 2025 at 12:26 PM
More #ASCO25 news this morning!
Feasibility questions about AstraZeneca's breast cancer drug: endpts.com/asco25-astra...
Researchers debate how to best use checkpoint inhibitors: endpts.com/asco25-resea...
Takeda and Protagonist's plenary data: endpts.com/asco25-taked...
Feasibility questions about AstraZeneca's breast cancer drug: endpts.com/asco25-astra...
Researchers debate how to best use checkpoint inhibitors: endpts.com/asco25-resea...
Takeda and Protagonist's plenary data: endpts.com/asco25-taked...